DWD. Weismann

D. Weismann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


D. Weismann has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adipositas und Herzinsuffizienz

    by D. Weismann, S. Wiedmann, M. Bala, S. Frantz, M. Fassnacht


  • Persistent Hypertension after successful resection of pheochromocytomas - results of a retrospective follow-up study

    by T Bergen, A Raida, M Fassnacht, F Weidemann, B Allolio, D Weismann

    Aims: Secondary hypertension consists a well-defined group of diseases, with pheochromocytomas being one of these entities. Clinical experience suggests that complete removal of pheochromocytomas improves blood pressure (BP); however, this was never formally demonstrated. Methods: We analysed resting BP, 24h-BP and metabolic parameters in 29 patients [11 females (mean-age 55.9 y), 18 males (mean-age 54.4 y)] with benign pheochromocytoma, who have had pheochromocytomas before. Diagnosis was based on symptoms, levels of plasma-metanephrines (M; 1177.53 ± 2379.64 ng/l) and normetanephrines (NM; 2155.75 ± 1739.89 ng/l), epinephrine (E; 108.38 ± 155.5 µg/d) and norepinephrine in 24h-urine (NE; 437.62 ± 520.11 µg/d) and tumors detected by computer tomography or MRI and up-take in MIBG-szintigraphy. The first plausible resting BP was taken from the charts. At follow-up, supine BP was measured after 20 minutes rest. Results: Mean follow-up was 6.2 years. At follow-up, plasma metanephrine (M: 27.39 ± 14.53 ng/l and NM: 61.71 ± 30.82 ng/l) levels as well as urine catecholamine were in the normal range. No relapse was diagnosed. In contrast, we found no difference in mean systolic (144 ± 35 vs. 137 ± 18 mmHg) and diastolic (85+/-18 vs. 82 ± 10 mmHg) BP and no significant differences in the number of antihypertensive medication taken (1.14 ± 1 vs. 1.17 ± 1.3). However, in 24h-blood pressure analysis BP was overall well controlled with antihypertensive medication. Interestingly, while 4 patients were on insulin treatment initially, only 2 patients had insulin at follow-up and 7 patients were on oral antiglycemic drug treatment while only 4 had OADs at follow-up. Conclusion: While the necessity of removal of pheochromocytomas is not questioned, our data show, that hypertension persists in a significant proportion of patients with an unchanged need for antihypertensive medication and the need for appropriate care and follow-up. However, no hypertensive crisis have been reported anymore.

  • The effect of a TRB-3 knockdown on cholesterol absorption in THP-1 cells and macrophages

    by M Kafka, B Heinze, S Sbierra, S Hahner, M Fassnacht, B Allolio, D Weismann

    Objective: A TRB-3 knockdown in insulin resistant mice decreased atherosclerosis. Suppression of TRB-3 in macrophages results in increased macrophage viability, increased adhesion of monocytes and increased phagocytosis. TRB-3 is induced by endoplasmatic reticulum (ER) stress. Aim: To describe the impact of TRB-3 on cholesterol uptake in monocytes (THP-1) and monocyte derived macrophages in vitro. Methods: THP-1 cells and monocytes were incubated with increasing concentrations of thapsigargin to promote ER-stress dependent TRB-3 expression. TRB-3 silencing by siRNA was implemented to prevent thapsigargin-induced TRB-3 induction. Expression of TRB-3 was measured by western blot (WB) and real time PCR (rt-pcr) analysis. The effect of modified TRB-3 expression on cholesterol absorption was investigated by measurement of bodipy®-labeled cholesterol influx using fluorescence spectrometry. Results: There is a low constitutive expression of TRB-3 in monocytes and macrophages. Stimulation with thapsigargin (0.5, 1, 1.5, 2 and 5µM) resulted in a significant (p < 0.05) increase in TRB-3 expression by 4.5-, 8.5-, 10.5-, 13.5-, and 19.5- fold, respectively. Concomitantly, there was a significant increase in ER-stress markers like BAX, CHOP and ATF4 (rt-pcr). TRB-3 siRNA decreased the expression of TRB- 3 in thapsigargin-treated cells (p < 0.05). Cholesterol uptake by control macrophages was higher (3- fold) compared to control monocytes. In macrophages, stimulation with 1.5µM und 5µM Thapsigargin resulted in a significant decrease in the absorption of cholesterol (p < 0.05). However, silencing of TRB-3 did not restore cholesterol uptake in macrophages. Conclusion: These data suggests that both in monocytes and in macrophages TRB-3 is induced by thapsigargin concomitantly to ER-stress. Furthermore, thapsigargin decreased cholesterol uptake in macrohpages. However, a knockdown of TRB-3 does not restore cholesterol uptake macrohpages in vitro.

  • Prevention of Hypertensive Crises in Rats Induced by Acute and Chronic Norepinephrine Excess

    by D. Weismann, K. Kleinbrahm, K. Hu, M. Fassnacht, S. Frantz, G. Ertl, B. Allolio, S. K. G. Maier

    Calcium Channel Blockers (CCBs), competitive α-adrenoceptor blockers, and phenoxybenzamine (POB) are used for preoperative treatment of pheochromocytomas. We analyzed the protection from hypertensive crisis provided by these drugs during acute and chronic norepinephrine excess. To ensure adaptive changes during chronic norepinephrine (NE) excess, we continuously exposed male Wistar rats to NE for 3 weeks (osmotic pumps). Afterwards, blood pressure (BP) was continuously measured while NE boli (0–1 000 μg/kg, i. v.) were administered before and after antihypertensive treatment in anesthetized and catheterized rats. A single dose of urapidil (10 mg/kg), nitrendipine (600 μg/kg) and POB (10 mg/kg) lowered BP from 212±12 mmHg by 52±7%, 31±9%, and 50±6%, respectively. With NE boli a maximum BP of 235±29, 240±30 and 138±3 mmHg was measured in urapidil, nitrendipine, and POB treated animals (p30 mmHg) was 3 (3), 1.5 (0–3), and 0 (0–1) (p, and 217±7 mmHg, p<0.01) and maximum blood pressure was 220±32, 282±26, and 268±40 mmHg (p<0.001) with NE boli. Further stabilization was achieved combining POB pretreatment with a continuous nifedipine infusion, which effectively prevented BP elevations during NE excess. POB was the most effective drug used in monotherapy, but BP stabilization was superior using a combination of POB pretreatment with a continuous nifedipine infusion in this model.


  • Mitotane Induces a Concentration-Dependent Impairment of Platelet Aggregation in Patients with Adrenocortical Carcinoma.

    by S Hahner, M Eigenthaler, D Weismann, B Allolio, M Fassnacht

    Article published by the Endocrine Society Article published by the Endocrine Society

  • Nebennieren und Diabetes mellitus

    by D. Weismann, B. Allolio

  • 674 Prognostic value of androgens in male patients with chronic heart failure

    by S Stoerk, G Gueder, S Frantz, J Bauersachs, D Weismann, B Allolio, G Ertl, C Angermann

  • The brazilian Arg337His germ line hot spot mutation in exon 10 of TP53 is infrequent in german patients with adrenocortical carcinoma

    by S. Hahner, A. C. Koschker, L. Herrmann, N. Reisch, D. Weismann, M. Fassnacht, B. Allolio

    Objective: An Arg337His germ line mutation in exon 10 of the TP53 tumour suppressor gene has been frequently identified in children and also in adults with sporadic adrenocortical carcinoma (ACC) in Brazil. This mutation has been described as a low penetrance mutation leading to an early onset of the disease. In the few described adult patients age at diagnosis was between 18 and 35 years and the mutation was associated with poor prognosis. Previous mutation analyses of TP53 in ACC have been confined mainly to the hot spot regions in exons 4–8 but not to exon 10. Methods: To investigate whether the Arg337His mutation in exon 10 plays a role in adrenocortical carcinogenesis also in other populations, we investigated 63 adult patients with ACC. Exon 10 was amplified from leucocyte DNA and mutation analysis was performed by RFLP and DNA sequencing. Results: The described Arg337His mutation was found in none of 50 unrelated controls and in only one 77-year old patient with metastatic ACC. Analysis of the corresponding tumour DNA revealed loss of heterozygosity at the 17p13 locus with deletion of the wild type allele. The diagnosis of a cortisol, estrogen and androgen producing ACC had been established in 2000 in this patient. Interestingly, he had been diagnosed also with colon cancer in 1993 and had developed prostate cancer 2 years after ACC. Family history revealed death from prostate cancer in the father at age 62 and death from breast cancer in the daughter at age 37. Up to now, onset of other types of cancer has not been described and the Arg337His mutation has been considered to be specific for adrenal carcinogenesis. Conclusions: The Arg337His germ line mutation is significantly less frequent in a German population with ACC compared to patients from southern Brazil (χ2 p=0.016) suggesting a founder effect. Furthermore, late manifestation of ACC and other malignancies not typically observed in the Li Fraumeni syndrome may be associated with this mutation.

  • Inhibition of IGF-II signal transduction improves chemosensitivity in human adrenocortical cancer cells

    by E. Beidinger, S. Hahner, A. Stürmer, A. C. Koschker, D. Weismann, M. Fassnacht, B. Allolio

    Objective: Treatment of adrenocortical carcinoma (ACC) is still unsatisfactory. As IGF-II and IGF-I receptor are frequently overexpressed in human ACC and inhibitors of the IGF system are currently under preclinical investigation interference with IGF-signaling might have an additive effect in antitumour treatment. Methods: We have analyzed several cytotoxic agents (etoposide, doxorubicine, cisplatin, streptocozin; 0.01–100µM) on adrenal cell proliferation in vitro and further investigated, whether inhibition of IGF-II signaling or downstream inhibition of mTOR via rapamycin affects chemotherapy response in the human adrenocortical cancer cell line NCI-h295 which is known to overexpress IGF-II. IGF-signaling was inhibited by specific antibodies against IGF-I receptor or IGF-II or by the small molecule IGF-I receptor antagonist H-1356. Results: Etoposide, doxorubicine and cisplatin inhibited cell proliferation with IC50 values of 1.2µM, 11µM and 9.6µM, respectively, whereas streptocozin was inactive in NCI-h295 cells. Inhibition of IGF-signaling reduced adrenal cell proliferation and significantly increased response to the chemotherapeutic agents at cytostatic doses within therapeutic ranges (e.g. inhibition by cisplatin, etoposide or doxorubicine 10µM alone or in combination with anti IGF-II 10µg/ml were 61% vs. 49%; 60% vs. 50% or 48% vs. 44% compared to controls, respectively; pConclusion: In adrenocortical cancer cells, IGF-II appears to be a protumourigenic growth factor reducing susceptibility to apoptosis and chemotherapeutic treatment. Interference with IGF-II activity may improve response of ACC to chemotherapeutic agents. However, effects detected in NCI-h295 cells after blockade of the IGF system were clearly weaker than the effects described in other non-adrenocortical cancer cells and the clinical relevance in vivo remains to be elucidated.